Abstract
Introduction
Diabetes is a complex set of diseases. Most commonly people with diabetes suffers from high blood sugar/glucose which in scientific term known as hyperglycaemia. It is a metabolic disorder in which body is unable to make enough insulin or it is not able to use insulin effectively or both [1] . There are broadly two categories of diabetes-type 1 diabetes and type 2 diabetes. There is another type of diabetes namely gestational diabetes which usually develops during pregnancy. Type 1 diabetes is caused by lack of insulin due to destruction of insulin producing beta cells (Islets of Langerhans) in the pancreas [1] . Thus, it is also known as insulin dependent diabetes mellitus. Type 1 diabetes is an autoimmune disease which usually occurs in children and young adults and thus it is sometimes also referred to as Juvenile diabetes [1] . The main causes of type 1 diabetes are -autoimmune destruction of Beta cells, genetic susceptibility, environmental factors, viruses and infections.
Type 2 diabetes is the commonest form of diabetes. It is caused by a combination of factors including insulin resistance, in which the body is unable to use the insulin effectively. Type 2 diabetes develops when the body is unable to compensate for the impaired ability to use insulin by producing enough insulin. The main causes of type 2 diabetes are-genetic susceptibility, obesity and physical inactivity, insulin resistance, abnormal glucose production by the liver, beta cell dysfunction [1].
According to global report on diabetes released by World Health Organization, Geneva 422 million people suffers from diabetes in 2014 (http://www.who.int/mediacentre/factsheets/en) [2] . The number is expected to increase to 552 million by 2030 [3] . The numbers suggest that 80% of the people with DM are living in low or middle income countries [3] . A number of researches are going on around the globe by pharmaceutical companies to exploit the huge market it provides.
Conventional Medicines and Future Drugs
No cure has yet been found for the disease; however, treatment modalities include lifestyle modifications, treatment of obesity, oral hypoglycemic agents, and insulin sensitizers like metformin, a biguanide that reduces insulin resistance, is still the recommended first line medication especially for obese patients. Other effective medications include non-sulfonylurea, thiazolidinediones, alpha glucosidase inhibitor, and insulin. The classification of conventional anti-diabetic medication and their mechanism of actions (www.drugs.com) [4] are listed in Table 1 . Recent research into the pathophysiology of type 2 DM has led to the introduction of new medications like glucagonlike peptide 1 analogous, dipeptidyl peptidase-IV inhibitors, inhibitors of the sodium-glucose cotransporter-2 and 11ß-hydroxysteroid dehydrogenase 1, insulin-releasing glucokinase activators and pancreatic-G-protein-coupled fatty-acid-receptor agonists, glucagon-receptor antagonists, metabolic inhibitors of hepatic glucose output and quick-release bromocriptine. Inhaled insulin was licensed for use in 2006 but has been withdrawn from the market because of low patronage [3] .
Dipeptidyl Peptidase-4 Inhibitors
Dipeptidyl Peptidase-4 Inhibitors (DPP-4) or in short gliptins falls in the newest class of drugs used for type 2 diabetes indications. DPP-4 is actually an enzyme which inhibits glucagon like peptide-1 or GLP-1. The function of GLP-1 is to trigger the β-cells of pancreas to release insulin. DPP-4 inhibitors stop DPP-4 enzyme from destroying GLP-1, which in turns stimulates β-cells of pancreas to release more insulin. Sitagliptin is an approved drug from FDA of this class. It is either used as a sole drug or in combination with metformin for the management of type 2 diabetes.
GLP-1 Mimetics (Incretin Mimetics)
GLP-1 is a hormone which is released from the digestive tract at the time of digestion. The function of GLP-1 is to stimulate the β-cells of pancreas to release more insulin. Since, a DPP-4 enzyme destroys GLP-1. The GLP-1 mimetic mimics the function of GLP-1 hormone and stimulates pancreas to release insulin. The GLP-1 synthetic mimetic agent is not recognized by DPP-4 enzyme as the same naturally occurring GLP-1 hormone. Exenatide is an injectable medication approved by FDA for the management of type 2 diabetes [5] . Liraglutide is another drug approved in this class.
Amylin Analog
Amylin is a hormone, which reduces glucagon. Glucagon is another hormone which causes the body to release or produce glucose. Thus, amylin analog indirectly influences the glucose level in the blood by reducing the glucagon level in the body [5] . Pramlinitide is an injectable medication approved by FDA for the management of type 2 diabetes.
Rimonabant
Endocannabinoid system (ECS) is a newly found physiological endocrine system that plays a key role in appetite and energy metabolism both in the brain as well as in the adipose tissue [6] [7] [8] . In the animal studies, it has been found that blocking ECS has led to weight loss and improved insulin sensitivity. By blocking CB1 receptors, rimonabant has been shown to reduce weight by suppressing appetite and by modifying glucose and fat metabolism [8] [9] [10] . Rimonabant has undergone phase 3 trials and is licensed for use in patients who have a BMI >30 kg/m 2 or BMI >27 kg/m 2 with an additional risk factor such as dyslipidaemia or diabetes [11] . 
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